The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).
 
Rui-hua Xu
No Relationships to Disclose
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
David Tougeron
Honoraria - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD; Roche; Sanofi; Servier/Pfizer
Consulting or Advisory Role - AstraZeneca; MSD; Pierre Fabre; Sanofi
Research Funding - AstraZeneca (Inst); BTG (Inst); MSD (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Sanofi
 
Yunxia Zuo
Employment - BeiGene; Hengrui Medicine
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene; Hengrui Medicine
 
Haiyuan Yang
Employment - BeiGene
 
Juan Zhang
Employment - BeiGene
 
Jingwen Shi
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)